gms | German Medical Science

60th Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Benelux countries and Bulgaria

German Society of Neurosurgery (DGNC)

24 - 27 May 2009, Münster

Association of the GNB3 825T-allele with better survival in patients with glioblastoma multiforme

Meeting Abstract

  • N. El Hindy - Klinik für Neurochirurgie, Universitätsklinikum Essen, Essen
  • M. Adamzik - Abteilung für Anästhesie und Intensivmedizin, Universitätsklinikum Essen, Essen
  • S. Asgari - Klinik für Neurochirurgie, Universitätsklinikum Essen, Essen
  • U. Sure - Klinik für Neurochirurgie, Universitätsklinikum Essen, Essen
  • W. Siffert - Institut für Pharmakogenetik, Universitätsklinikum Essen, Essen
  • I. Sandalcioglu - Klinik für Neurochirurgie, Universitätsklinikum Essen, Essen

Deutsche Gesellschaft für Neurochirurgie. 60. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit den Benelux-Ländern und Bulgarien. Münster, 24.-27.05.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocDI.09-02

doi: 10.3205/09dgnc168, urn:nbn:de:0183-09dgnc1680

Published: May 20, 2009

© 2009 El Hindy et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: Genotypes of the C825T polymorphism of the GNB3 gene encoding the G-protein ß3 subunit were recently associated with the prognosis of different malignant tumors. We investigated potential associations of GNB3 genotypes with survival of patients with glioblastoma multiforme (GBM).

Methods: Between 2002 and 2005, a total of 225 consecutive patients underwent surgery for GBM at our department. In this patient group, tumor material, DNA extraction and follow up for at least 24 months was available for 161 patients. DNA was extracted from paraffin embedded tumour tissue. Genotype distribution and allele frequencies of the GNB3 polymorphism were determined. Patients were divided into those with gross total resection (GTR) and those who underwent any stereotactic biopsy (SB). The data were evaluated with respect to the basic clinical data, adjuvant therapy as well as to survival at the 2-year follow up.

Results: At the 2-year follow-up, 128 (79.5%) of the 161 patients had died, while 33 (20.5%) were alive. We found a significantly higher rate of survival for homo- and heterozygous T-allele carriers (p=0.019) with 38.5% and 25.3%, respectively, but only 11.6% for homozygous C-allele carriers. In the GTR subgroup, the survival rate increased to 57.1% for homozygous T-allele carriers, 36.4% for heterozygous T-allele carriers, but only 17.1% for homozygous C-allele carriers (p=0.038). In the SB subgroup, no differences on the survival rate were found.

Conclusions: Our data suggest a possible association of the GNB3 825T-allele and survival in patients with GBM. The effects observed in our study proved to be closely dependent on the quantity of tumor resection. C-allele carrier might be at a higher risk for an advanced tumor stage and unresectability. Further studies are necessary to determine the exact mechanisms leading to these observations.